Navigation Links
Essilor to Acquire 50% of Shamir Optical
Date:10/15/2010

ore impact of the purchase price allocation).

This news release is provided for information purposes only and does not constitute an offer to purchase any security, nor is it a solicitation of any vote or approval in any jurisdiction.

Shareholders of Shamir Optical should be aware that the consummation of the merger proposal is subject to various conditions, including the requisite shareholder vote described above, and therefore the merger proposal may not be consummated. Persons who are in doubt as to the action they should take should consult their stockbroker, bank manager, attorney or other professional advisers.

Where You Can Obtain Further Information

Details of the merger proposal will be contained in a document (the "Information Statement ") to be mailed to the shareholders of Shamir Optical in due course. In addition, since the merger proposal constitutes a "going private transaction" subject to the requirements of Rule 13e-3 under the U.S. Securities Exchange Act of 1934, a Schedule 13E-3 will be filed as required with the United States Securities and Exchange Commission (the "SEC"). All shareholders are urged to read the Schedule 13E-3, the Information Statement and any other definitive materials accompanying those documents before casting any vote at (or providing any proxy for) the special meeting of the shareholders. Shareholders may obtain such documents free of charge when they are furnished to the SEC and become available at the Web site maintained by the SEC (http://www.sec.gov).

About Shamir Optical

Shamir Optical is a leading provider of innovative products and technology to the spectacle lens market. Shamir Optical's leading lenses are marketed under a variety of trade names, including Shamir Creation(TM), Shamir Piccolo(TM), Shamir Office(TM), Shamir Autograph(TM), Shamir Attitude(TM) and Shamir Smart(TM). Shamir Optical is one of the world's preeminent research an
'/>"/>

SOURCE Essilor
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Essilor : First Half 2009 Revenue
2. Essilor: Essilor Forges New Strategic Partnerships Around the World
3. Essilor : 2009 First Quarter Report
4. Essilor Cancels 1,600,000 Shares
5. Essilor Finalizes Satisloh Agreement
6. Essilors First-Half 2008 Results
7. Essilor : Nomination of Hubert Sagnieres
8. Cell Biosciences to Acquire Convergent Bioscience
9. Met-Pro Corporation Acquires Patented Biological Technology
10. Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company
11. Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
(Date:8/27/2014)... 2014  A novel biomarker for rheumatoid arthritis ... identify early-stage disease, when treatment can often arrest ... new study in The Journal of Rheumatology. ... DGX ) and other institutions found that elevated ... antibody-serum testing, including rheumatoid factor (RF) and anti-citrullinated ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... of Guggenheim Partners, today announced the hiring of veteran ... and senior equity analyst. Mr. Butler will focus on ... brings our team a wealth of experience and a ... Dante Ferrarie , Senior Managing Director and Head of ...
(Date:8/27/2014)... August 27, 2014 Flagship Biosciences LLC, ... services to the pharmaceutical and medical device industries, has ... The fast growing company has consolidated its histology and ... Boulder to Westminster, CO, just north of Denver. ... 7575 W. 103rd Ave., Suite 100, Westminster, CO 80021 ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2
... NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ - ICBS Ltd. ... state and municipal regulatory bodies for the sale of the ... Solutions will be moving to target regulatory agencies in the ... advantages not only on time advantage (10 Hours for test ...
... III trials of OGX-011 in first- and second-line advanced ... begin in 2010 and early 2011 -- , -- ... to target resistance to cancer treatments -- , JERUSALEM, ... - Teva Pharmaceutical Industries Ltd. ( TEVA) and OncoGenex ...
... , , THOUSAND OAKS, Calif., Dec. ... Roger M. Perlmutter, M.D., Ph. D., Amgen,s executive vice ... Fellow of the American Association for the Advancement of Science ... on behalf of the advancement of science or its applications ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 2Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 3
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have shown that excessive iron is closely ... Previous studies from Chunyan Guo and co-workers ... shown that baicalin prevented iron accumulation after ... 1 expression, and increased ferroportin 1 expression ... disease rats. However, the relationship between iron ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... at the U.S. Department of Energy,s Lawrence Berkeley National ... into wispy nanoscale ropes that approach the structural complexity ... development in the push to develop self-assembling nanoscale materials ... but which are rugged enough to withstand harsh conditions ...
... Energy,s Pacific Northwest National Laboratory has been recognized for ... The award-winning partnerships are helping analyze trace amounts of ... and more easily study live cells., The Federal Laboratory ... 2011 for Excellence in Technology Transfer. The consortium is ...
... have proven that you don,t have to travel to exotic ... distinctive species of crayfish in Tennessee and Alabama that is ... genetic relative, once thought to be the only species in ... in Kentucky, can grow almost as big as a lobster. ...
Cached Biology News:A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 2A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 3PNNL recognized for technology transfer 2PNNL recognized for technology transfer 3Researchers discover giant crayfish species right under their noses 2Researchers discover giant crayfish species right under their noses 3Researchers discover giant crayfish species right under their noses 4
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... 1.(Note: the amino acid sequence is proprietary)(Peptide ... Entrez GeneID: 1822 ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: